Drug profile

The FDA adverse-event record for Methocarbamol

599 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Methocarbamol. See the species affected, top reactions, and outcomes below.

599
adverse-event reports
22.9%
death-coded share
Dog
most-reported species
124
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
599
Total Reports
137
Deaths Reported
22.9%
Death Rate

Active Ingredients

Methocarbamol

Administration Routes

UnknownOralIntravenousSubcutaneousRectal

Species Affected

Dog 553
Cat 39
Horse 5
Unknown 1
Human 1

Most Affected Breeds

Retriever - Labrador 58
Domestic Shorthair 29
Chihuahua 26
Dachshund (unspecified) 25
Beagle 23
Crossbred Canine/dog 21
Shepherd Dog - German 18
Bulldog - French 18
Shih Tzu 18
Terrier - Bull - American Pit 15

Most Reported Reactions

Vomiting 124
Death by euthanasia 90
Seizure NOS 86
Lethargy (see also Central nervous system depression in 'Neurological') 81
Ataxia 78
Diarrhoea 65
Anorexia 61
Other abnormal test result NOS 50
Abnormal radiograph finding 49
Elevated alanine aminotransferase (ALT) 49
Pain NOS 49
Tremor 49

Outcome Breakdown

Ongoing
242 (40.5%)
Outcome Unknown
110 (18.4%)
Recovered/Normal
103 (17.2%)
Euthanized
90 (15.1%)
Died
47 (7.9%)
Recovered with Sequela
6 (1.0%)

Methocarbamol Adverse Event Insights

599 reports name Methocarbamol; 137 recorded a death outcome (22.9% of reported events, not a population-level mortality rate). Active ingredient: Methocarbamol. Administration routes: Unknown, Oral, Intravenous, Subcutaneous.

By species: Dog (553 reports), Cat (39 reports), Horse (5 reports). By breed: Retriever - Labrador (58), Domestic Shorthair (29), Chihuahua (26).

Leading clinical signs: Vomiting (124), Death by euthanasia (90), Seizure NOS (86), Lethargy (see also Central nervous system depression in 'Neurological') (81). Outcome, 598 coded reports: Ongoing leads at 40.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.